TipRanks

Notifications

H.C. Wainwright Keeps a Buy Rating on Mirum Pharmaceuticals (MIRM)

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Mirum Pharmaceuticals (MIRMResearch Report) today and set a price target of $51.00. The company’s shares closed last Tuesday at $19.39.

According to TipRanks.com, Arce is a 5-star analyst with an average return of 18.5% and a 41.7% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Aurinia Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Mirum Pharmaceuticals with a $46.50 average price target, implying a 144.7% upside from current levels. In a report issued on September 13, Guggenheim also maintained a Buy rating on the stock with a $37.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $26.31 and a one-year low of $13.85. Currently, Mirum Pharmaceuticals has an average volume of 90.67K.

Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MIRM in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O’Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.

Read More on MIRM: